SCHEMBL19963545

SCHEMBL19963545

CCCCCC(CCC)C(C(=O)O)c1ccco1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN7 P35236 1/20 0.42
BLM P54132 1/20 0.42
ESR2 Q92731 1/20 0.42
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
RECQL P46063 1/20 0.38
HDAC3 O15379 1/20 0.37
CNR2 P34972 1/20 0.37
GPR84 Q9NQS5 3/20 0.37
FFAR1 O14842 1/20 0.37
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19097833 0.90 ALDH1A1 (0.42) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL11847308 0.78 KMT2A (0.46) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL7795384 0.74 KMT2A (0.43) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL10443233 0.74 CYP2D6 (0.52) POLBALDH1A1CNR2GPR84FFAR1
SCHEMBL10443338 0.74 CYP2D6 (0.52) POLBALDH1A1CNR2GPR84FFAR1
SCHEMBL31447436 0.74 CYP2D6 (0.52) POLBALDH1A1CNR2GPR84FFAR1
SCHEMBL10963512 0.73 KMT2A (0.52) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL2139138 0.73 KMT2A (0.50) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL30264728 0.73 KMT2A (0.42) L3MBTL1KMT2APOLBPKMPTPN1
SCHEMBL5613043 0.72 KMT2A (0.52) L3MBTL1KMT2APOLBPKMPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10723737-B2 Compositions and methods for treating neurodegenerative diseases and cardiomyopathy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-07-28 US disclosed
US-20180072731-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY MITOKININ, INC. 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072731-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY PINK1, CKMT1A; CKMT1B, NLN L3MBTL1 1080/4885KMT2A 3562/4885POLB 1319/4885
US-10723737-B2 Compositions and methods for treating neurodegenerative diseases and cardiomyopathy PINK1, CKMT1A; CKMT1B, NLN L3MBTL1 1080/4885KMT2A 3562/4885POLB 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.